scholarly journals Risk Factors for Lymphatic Metastasis of Malignant Bone and Soft-Tissue Tumors

Medicine ◽  
2014 ◽  
Vol 93 (27) ◽  
pp. e225 ◽  
Author(s):  
Takashi Yanagawa ◽  
Kenichi Saito ◽  
Kenji Takagishi
Keyword(s):  
Risk Factors ◽  
Soft Tissue ◽  
Lymphatic Metastasis ◽  
Soft Tissue Tumors

scholarly journals Prevalence of Psychological Distress and Its Risk Factors in Patients with Primary Bone and Soft Tissue Tumors

Healthcare ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 566
Author(s):  
Masato Ise ◽  
Eiji Nakata ◽  
Yoshimi Katayama ◽  
Masanori Hamada ◽  
Toshiyuki Kunisada ◽  
...  
Keyword(s):  
Risk Factors ◽  
Psychological Distress ◽  
Soft Tissue ◽  
Rating Scale ◽  
Numeric Rating Scale ◽  
Soft Tissue Tumors ◽  
Number Of Patients ◽  
Primary Bone ◽  
Associated Risk Factors ◽  
Numeric Rating

Psychological distress is common in patients with soft tissue and bone tumors. We first investigated its frequency and the associated risk factors in patients with pre-operative bone and soft tissue tumors. Participants included 298 patients with bone and soft tissue tumors who underwent surgery in our institution between 2015 and 2020. Psychological distress was evaluated by the Distress and Impact Thermometer (DIT) that consists of two types of questions (questions about the severity of the patient’s distress (DIT-D) and its impact (DIT-I)). We used a cut-off point of 4 on the DIT-D and 3 on the DIT-I for screening patients with psychological distress. We therefore investigated: (1) the prevalence of psychological distress as assessed with DIT or distress thermometer (DT), which can be decided by DIT-D ≥ 4, (2) what are the risk factors for the prevalence of psychological distress, and (3) what is the number of patients who consulted a psychiatrist for psychological distress in patients with pre-operative bone and soft tissue tumors. With DIT and DT, we identified 64 patients (21%) and 95 patients (32%), respectively, with psychological distress. Multivariate logistic regression revealed that older age, sex (female), malignancy (malignant or intermediate tumor), a lower Barthel Index, and higher numeric rating scale were risk factors for psychological distress. Two patients (3%) consulted a psychiatrist after surgery. In conclusion, careful attention to psychological distress is needed, especially for female patients, older patients, and those with malignant soft or bone tissue tumors who have more than moderate pain.

Prevalence of Symptomatic Venous Thromboembolism in Patients with Malignant Bone and Soft Tissue Tumors Undergo Surgery without Chemoprophylaxis

2021 ◽  
Vol 104 (5) ◽  
pp. 728-732
Keyword(s):  
Risk Factors ◽  
Pulmonary Embolism ◽  
Venous Thromboembolism ◽  
Soft Tissue ◽  
Soft Tissue Tumor ◽  
Significant Risk ◽  
Soft Tissue Tumors ◽  
Tumor Patients ◽  
Tissue Tumor ◽  
Picture Archiving And Communication

Background: The prevalence and risk factors of venous thromboembolism (VTE) in malignant bone and soft tissue tumor patients that undergo surgery is reported in many studies. However, there is lack of studies on the patients without chemoprophylaxis. Objective: To evaluate the prevalence and risk factors for VTE after surgery in malignant bone and soft tissue tumor patients without chemoprophylaxis Materials and Methods: A retrospective medical chart review identified 260 cases of malignant bone and soft tissue tumor operated between 2008 and 2017. Official diagnostic reports were reviewed from the Picture Archiving and Communication System (PACs). The incidence of VTE and its risk factors were assessed using Chi-square test, t-test, and binary logistic regression. Results: The overall prevalence of symptomatic VTE was 0.8% (2/260 patients), all of which had PE. No fatal VTE was detected. Asymptomatic pulmonary embolism (PE) was identified in two patients (0.8%) Mean follow up interval of the available data was 9.5 (3 to 36) months. No significant risk factor was found. Conclusion: The authors found that patients with malignant bone and soft tissue tumors that underwent surgery without chemoprophylaxis in the authors’ center had lower prevalence of VTE when compared to most previous studies whose patient received chemoprophylaxis. Keywords: Venous thromboembolism, Sarcoma, Cancer, Deep vein thrombosis, Pulmonary embolism, Thromboprophylaxis, Chemoprophylaxis

scholarly journals Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0254866
Author(s):  
Hisaki Aiba ◽  
Hiroaki Kimura ◽  
Satoshi Yamada ◽  
Hideki Okamoto ◽  
Katsuhiro Hayashi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Soft Tissue ◽  
Time Course ◽  
Lung Tumor ◽  
Case Series ◽  
Metastatic Lesion ◽  
Soft Tissue Tumors ◽  
Visceral Pleura ◽  
Central Type ◽  
Metastatic Lesions

To investigate pneumothorax patterns in pazopanib treatment by focusing on the positional relationship between the visceral pleura and metastatic lung tumor, we examined 20 patients with advanced soft tissue tumors who developed lung metastases and underwent pazopanib treatment between 2012 and 2019. Pneumothorax was classified into two types based on the location of the metastatic lesion around the visceral pleural area before pazopanib treatment: subpleural type, within 5 mm from the pleura; and central type, >5 mm from the pleura. We investigated the rates of pneumothorax and the associated risk factors. Five patients experienced pneumothorax (three subpleural and two central types). Cavitation preceded pneumothorax in 83% of patients and led to connection of the cavitated cyst of the metastatic lesion to the chest cavity in the shorter term in patients with the subpleural type. Conversely, a more gradual increase in the cavity size and sudden cyst rupture were observed in the central type. The risk factors for pneumothorax were cavitation after initiating pazopanib and intervention before pazopanib, either ablation or surgery. The location of the metastatic lesions was not a risk factor for the occurrence of pneumothorax. In conclusion, pneumothorax is an adverse event associated with pazopanib treatment. Therefore, attention must be paid to predisposing factors such as the formation of cavitation after pazopanib initiation and previous interventions to the lungs. Moreover, because subpleural pneumothorax tends to occur earlier than the central type, a different time course can be anticipated based on the positional relationships of the metastatic lesions to the visceral pleura.

scholarly journals Inflammatory Myofibroblastic Tumor in the Inguinal canal: A Rare Case Report

2022 ◽  
Author(s):  
Arpankumar Patel ◽  
Rutikbhai Desai ◽  
Hilloni Shah ◽  
Laseena Vaisyambath ◽  
Manozna Karri ◽  
...  
Keyword(s):  
Risk Factors ◽  
Soft Tissue ◽  
Inflammatory Myofibroblastic Tumor ◽  
Case Reports ◽  
Symptomatic Treatment ◽  
Soft Tissue Tumors ◽  
Anaplastic Lymphoma ◽  
Rare Case Report ◽  
Inflammatory Pseudotumors ◽  
Specific Symptoms

Abstract Background Inflammatory myofibroblastic tumors, previously known as inflammatory pseudotumors, are rare soft tissue carcinomas with variable presentation and location. Due to non-specific symptoms and location, the diagnosis of this condition is often clinically challenging. Only a handful of case reports have been published in the literature describing this tumor, and there is still a lack of consensus on pathogenesis, risk factors, and treatment strategy. Most tumors have shown mutation in the anaplastic lymphoma receptor tyrosine kinase (ALK) gene. In this article, we describe a case of ALK-negative malignant inflammatory myofibroblastic tumor. Case A 46 years old male with no risk factors presented with a mass in the inguinal region. The ultrasound was suggestive of a mixed echoic mass suggestive of inguinal hernia, which led to surgical repair with resection of the tumor segment. Subsequently, histopathology and immunohistochemistry confirmed that the mass was an inflammatory myofibroblastic tumor which then recurred in a few years and failed to respond to multiple chemotherapy regimens, and over time, it progressively metastasized to the anterior abdominal wall and lungs. The patient is currently receiving palliative chemotherapy and symptomatic treatment. Conclusion This rare soft tissue tumor has not received much attention, and clinicians often miss the diagnosis. We stress that further study should be carried out on these soft tissue tumors, and adequate diagnostic and therapy recommendations should be developed.

Different Patterns of Pneumothorax in Patients With Soft Tissue Tumors Treated With Pazopanib

2020 ◽  
Author(s):  
Hisaki Aiba ◽  
Hiroaki Kimura ◽  
Satoshi Yamada ◽  
Hideki Okamoto ◽  
Katsuhiro Hayashi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Soft Tissue ◽  
Time Course ◽  
Lung Tumor ◽  
Lung Metastases ◽  
Metastatic Lesion ◽  
Soft Tissue Tumors ◽  
Visceral Pleura ◽  
Metastatic Lung Tumor ◽  
Central Type

Abstract Background: To investigate the patterns of pneumothorax in pazopanib treatment, focusing on the positional relationship between the visceral pleura and metastatic lung tumor. Methods: We examined 20 patients with advanced soft tissue tumor who developed lung metastases before pazopanib treatment during 2012–2019. Pneumothorax was classified into two types based on the location of the metastatic lesion around the visceral pleural area before pazopanib treatment: subpleural type, within 5 mm from the pleura; central type, > 5 mm from the pleura. We investigated the rates of pneumothorax and the risk factors. Results: Overall, 5 patients experienced pneumothorax (3 subpleural and 2 central type). Cavitation preceded pneumothorax in 80% of the patients and led to connection of the cavitated cyst of the metastatic lesion to the chest cavity in a shorter term in those with the subpleural type. Conversely, a more gradual increase in cavity and sudden cyst rupture were observed in the central type. The risk factors for pneumothorax were cavitation after the initiation of pazopanib and previous intervention before pazopanib including ablation or surgery. The locations of metastatic lesion were not risk factor for the occurrence of pneumothorax.Conclusion: Pneumothorax is an adverse event of pazopanib treatment. Therefore, attention must be paid to the predisposing factors such as the formation of cavitation after pazopanib initiation and previous interventions on the lungs. Moreover, as the subpleural pneumothorax tends to occur earlier than the central type, the different time course can be anticipated based on the positional relationships of the metastatic lesions to the visceral pleura.

The Genetic Risk Factors for Bone and Soft Tissue Tumors

1994 ◽  
Vol 3 (3) ◽  
pp. 599-607
Author(s):  
Sheila M. McGuire ◽  
Anne L. McGuire ◽  
Michael H. McGuire
Keyword(s):  
Risk Factors ◽  
Soft Tissue ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Soft Tissue Tumors

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

1973 ◽  
Vol 31 ◽  
pp. 404-405
Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Tumor Tissue ◽  
Soft Tissue Tumors ◽  
Clinical Usefulness ◽  
Electron Microscopic ◽  
Normal Cells ◽  
Electron Microscopic Autoradiography ◽  
Peritoneal Cells ◽  
Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Percutaneous Imaging-Guided versus Open Musculoskeletal Biopsy: Concepts and Controversies

2020 ◽  
Vol 24 (06) ◽  
pp. 667-675
Author(s):  
Violeta Vasilevska Nikodinovska ◽  
Slavcho Ivanoski ◽  
Milan Samardziski ◽  
Vesna Janevska
Keyword(s):  
Soft Tissue ◽  
Complication Rate ◽  
Core Needle Biopsy ◽  
Multidisciplinary Team ◽  
Gold Standard ◽  
Needle Biopsy ◽  
Soft Tissue Tumors ◽  
Open Biopsy ◽  
Core Needle ◽  
Similar Accuracy

AbstractBone and soft tissue tumors are a largely heterogeneous group of tumors. Biopsy of musculoskeletal (MSK) tumors is sometimes a challenging procedure. Although the open biopsy is still considered the gold standard for the biopsy of MSK lesions, core needle biopsy can replace it in most cases, with similar accuracy and a low complication rate. The biopsy should be performed in a tertiary sarcoma center where the multidisciplinary team consists of at minimum a tumor surgeon, an MSK pathologist, and an MSK radiologist who can assess all steps of the procedure. Several factors can influence the success of the biopsy including the lesion characteristics, the equipment, and the method used for the procedure. This review highlights some of the important aspects regarding the biopsy of the MSK tumors, with special attention to imaging a guided core needle biopsy and highlighting some of the recent advancements and controversies in the field.

Sign in / Sign up

Export Citation Format

Share Document